SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: May 16, 1996
(Date of earliest event reported)
LIDAK PHARMACEUTICALS
(Exact name of registrant as specified in its charter)
CALIFORNIA
(State or other jurisdiction of incorporation)
0-18734 33-0314804
(Commission File Number) (IRS Employer
Identification No.)
11077 North Torrey Pines Road, La Jolla, California 92037
(Address of principal executive offices) (Zip code)
(619) 558-0364
(Registrants telephone number, including area code)
<PAGE>
Item 5. OTHER EVENTS
On May 16, 1996 the Company reported new data regarding
pain relief and additional new healing-time data from its Phase
3 U.S./Canadian clinical trials of n-docosanol 10% cream
(LIDAKOL(R)) as a topical treatment for recurrent oral herpes.
In the clinical trials, a total of 1192 patients were divided
among two early-stage studies and one late-stage study. Early-
stage treatment was started during the onset of oral herpes
episodes before development of a blister. Late-stage treatment
was started after blisters and/or ulcers had already appeared.
The Company reported that the new data suggest that
treatment with LIDAKOL or the intended placebo in the two early
stage treatment studies shortens the duration of pain symptoms
associated with recurrent herpes episodes. In these two
studies, respectively, patients experienced complete elimination
of pain in 2.6 and 4.0 days compared to 6.0 days when the
disease is left untreated, as published in the scientific
literature. The Company also reported that the late stage
clinical trial demonstrated that late-stage treatment with
either LIDAKOL or the intended placebo was ineffective in
altering overall healing times in recurrent oral herpes episodes
and that data on possible treatment benefits or pain symptoms at
these later stages were inconclusive. Finally, the Company
reported that it will be necessary for it to conduct additional
clinical trials to prove the efficacy of LIDAKOL before it can
apply for FDA marketing approval.
On its Form 8-K filed on March 14, 1996, LIDAK had reported
preliminary results from the two early-stage treatment studies
regarding overall time-to-healing and frequency of aborted
episodes.
SIGNATURES
Pursuant to the requirements of the Securities and
Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly
authorized.
LIDAK PHARMACEUTICALS
Date: May 22, 1996 By:/s/Michael H. Lorber
------------------------------
Vice President/CFO & Secretary
